Discover FEMARA® (letrozole), an approved treatment from Novartis Oncology for HR+ breast cancer in postmenopausal women. Learn about FEMARA® side effects & see recommended FEMARA® dosage information.

2.50 Rating by CuteStat

femara.com is 2 decades 6 years old. It is a domain having com extension. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats were reported recently by users, femara.com is SAFE to browse.

PageSpeed Score
0
Siteadvisor Rating
No Risk Issues

Traffic Report

Daily Unique Visitors: Not Applicable
Daily Pageviews: Not Applicable

Estimated Valuation

Income Per Day: $ 0.15
Estimated Worth: $ 8.95

Search Engine Indexes

Google Indexed Pages: Not Applicable
Bing Indexed Pages: Not Applicable

Search Engine Backlinks

Google Backlinks: 599,000
Bing Backlinks: Not Applicable

Safety Information

Google Safe Browsing: No Risk Issues
Siteadvisor Rating: No Risk Issues
WOT Trustworthiness: Not Applicable
WOT Child Safety: Not Applicable

Website Ranks & Scores

Alexa Rank: Not Applicable
Domain Authority: Not Applicable

Web Server Information

Hosted IP Address:

217.114.92.50

Hosted Country:

Sweden SE

Location Latitude:

59.3247

Location Longitude:

18.056

Page Resources Breakdown

Homepage Links Analysis

Website Inpage Analysis

H1 Headings: 2 H2 Headings: Not Applicable
H3 Headings: 1 H4 Headings: Not Applicable
H5 Headings: Not Applicable H6 Headings: Not Applicable
Total IFRAMEs: 3 Total Images: 7
Google Adsense: Not Applicable Google Analytics: Not Applicable

Websites Hosted on Same IP (i.e. 217.114.92.50)

Temporary Page

- setyoursights.com
5,768,785 $ 240.00

AFINITOR® (everolimus) | Official Site from Novartis

- afinitor.com

The official website for AFINITOR® (everolimus) tablets. Find information about AFINITOR®, the conditions it treats, and Important Safety Information.

2,946,082 $ 480.00

SANDOSTATIN® LAR Depot (octreotide acetate) for Acromegaly and Carcino

- sandostatin.com

Learn about SANDOSTATIN® LAR Depot (octreotide acetate) for injectable suspension for acromegaly and carcinoid syndrome. See Important Safety Information.

Not Applicable $ 8.95

Home | EXJADE® (deferasirox) FILM-COATED TABLETS

- exjade.com

Learn about EXJADE®, an iron chelation therapy for the management of chronic iron overload due to blood transfusions. See safety & product information.

9,205,258 $ 240.00

TYKERB® (lapatinib) | HR+, HER2+ Metastatic Breast Cancer

- tykerb.com

Learn about TYKERB® (lapatinib), approved to treat HR+ and HER2+ metastatic breast cancer. Find Important Safety Information and BOXED WARNING.

5,943,198 $ 240.00

HTTP Header Analysis

HTTP/1.0 200 OK
Cache-Control: private
Content-Type: text/html; charset=utf-8
Date: Fri, 27 Dec 2019 22:33:30 GMT
Server: ECAcc (saa/83DD)
Strict-Transport-Security: max-age=31536000; includeSubDomains
Via: 1.1 sjc1-bit25
X-Content-Type-Options: nosniff
X-Frame-Options: SAMEORIGIN
X-XSS-Protection: 1; mode=block
Content-Length: 51634
Connection: close

Domain Information

Domain Registrar: MarkMonitor, Inc.
Registration Date: Sep 3, 1997, 12:45 PM 2 decades 6 years 8 months ago
Expiration Date: Sep 1, 2020, 12:45 PM 3 years 8 months 1 week ago
Domain Status:
clientupdateprohibited
clienttransferprohibited
clientdeleteprohibited

Domain Nameserver Information

Host IP Address Country
dns1.novartis.com 160.62.4.7 Switzerland Switzerland
dns2.novartis.com 160.62.7.59 Switzerland Switzerland
dns3.novartis.com 160.62.14.115 United States of America United States of America
dns4.novartis.com 160.62.14.116 United States of America United States of America

DNS Record Analysis

Host Type TTL Extra
femara.com A 10798 IP: 217.114.92.50
femara.com NS 86400 Target: dns1.novartis.com
femara.com NS 86400 Target: dns2.novartis.com
femara.com NS 86400 Target: dns3.novartis.com
femara.com NS 86400 Target: dns4.novartis.com
femara.com SOA 3600 MNAME: dns1.novartis.com
RNAME: hostmaster.novartis.com
Serial: 2019062001
Refresh: 28800
Retry: 7200
Expire: 604800
Minimum TTL: 3600
femara.com TXT 86400 TXT: 12c8b2cb-fc50-45e0-91b6-3f382de0d8e7

Full WHOIS Lookup

Domain Name: femara.com
Registry Domain ID: 451762_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2019-12-27T00:10:02-0800
Creation Date: 1997-09-03T00:00:00-0700
Registrar Registration Expiration Date: 2020-09-01T00:00:00-0700
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: abusecomplaints@markmonitor.com
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited)
Domain Status: clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited)
Domain Status: clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited)
Registrant Organization: Novartis AG
Registrant State/Province:
Registrant Country: CH
Admin Organization: MarkMonitor, Inc.
Admin State/Province: ID
Admin Country: US
Tech Organization: MarkMonitor, Inc.
Tech State/Province: ID
Tech Country: US
Name Server: dns2.novartis.com
Name Server: dns4.novartis.com
Name Server: dns3.novartis.com
Name Server: dns1.novartis.com
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2019-12-27T14:33:37-0800 <<<

For more information on WHOIS status codes, please visit:
https://www.icann.org/resources/pages/epp-status-codes

If you wish to contact this domain’s Registrant, Administrative, or Technical
contact, and such email address is not visible above, you may do so via our web
form, pursuant to ICANN’s Temporary Specification. To verify that you are not a
robot, please enter your email address to receive a link to a page that
facilitates email communication with the relevant contact(s).

Web-based WHOIS:
https://domains.markmonitor.com/whois

If you have a legitimate interest in viewing the non-public WHOIS details, send
your request and the reasons for your request to whoisrequest@markmonitor.com
and specify the domain name in the subject line. We will review that request and
may ask for supporting documentation and explanation.

The data in MarkMonitor’s WHOIS database is provided for information purposes,
and to assist persons in obtaining information about or related to a domain
name’s registration record. While MarkMonitor believes the data to be accurate,
the data is provided "as is" with no guarantee or warranties regarding its
accuracy.

By submitting a WHOIS query, you agree that you will use this data only for
lawful purposes and that, under no circumstances will you use this data to:
(1) allow, enable, or otherwise support the transmission by email, telephone,
or facsimile of mass, unsolicited, commercial advertising, or spam; or
(2) enable high volume, automated, or electronic processes that send queries,
data, or email to MarkMonitor (or its systems) or the domain name contacts (or
its systems).

MarkMonitor.com reserves the right to modify these terms at any time.

By submitting this query, you agree to abide by this policy.

MarkMonitor is the Global Leader in Online Brand Protection.

MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiCounterfeiting(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services

Visit MarkMonitor at https://www.markmonitor.com
Contact us at +1.8007459229
In Europe, at +44.02032062220